UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000025158 |
|---|---|
| Receipt number | R000028933 |
| Scientific Title | A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension |
| Date of disclosure of the study information | 2016/12/07 |
| Last modified on | 2022/03/11 14:11:08 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Acronym
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Scientific Title
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Scientific Title:Acronym
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Region
| Japan | North America | South America |
| Australia | Europe |
Condition
Condition
Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Classification by specialty
| Cardiology | Pneumology | Clinical immunology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To assess the efficacy of bardoxolone methyl relative to placebo.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Phase III
Assessment
Primary outcomes
Change from baseline in six-minute-walk distance (6MWD) relative to placebo at Week 24
Key secondary outcomes
*Improvement by at least one WHO functional class
*Increase from baseline in 6MWD by at least 10%
*Decrease from baseline in creatine kinase (as a surrogate biomarker for muscle injury and
inflammation) by at least 10%
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
YES
Dynamic allocation
NO
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Drug: Bardoxolone Methyl
Bardoxolone methyl dose escalated to a maximum of 10 mg. Dosing period is up to 6 months.
Interventions/Control_2
Drug: Placebo Oral Capsule
Capsule containing an inert placebo is administrated up to 6 months.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1 Adult male and female patients 18 to 75 years of age upon study consent;
2 BMI 18.5 kgm2
3 Symptomatic pulmonary hypertension WHONYHA FC class II and III
4 WHO Group I PAH associated with connective tissue disease
5 Had a diagnostic right heart catheterization performed and documented within 36months prior to Day 1 that confirmed a diagnosis of PAH according to all the following criteria:
a Mean pulmonary artery pressure 25 mm Hg (at rest)
b Pulmonary capillary wedge pressure (PCWP)15 mm Hg
c Pulmonary vascular resistance 240 dyn seccm5 or 3 mm Hg/liter (L)min
6 Has BNP level 400 pg/mL
7 Had an average 6MWD 150 meters on two consecutive tests performed on different days prior to randomization, with both tests measuring within 15% of one another;
8 Has been receiving no more than two approved disease-specific PAH therapies. PAH therapy must have been at a stable dose for at least 90 days prior to Day 1. No additions or changes should be made to PAH therapies and doses should remain stable for the duration of the study;
6 Has BNP level 400 pmL
7 Had an average 6MWD 150 meters on two consecutive tests performed on different days prior to randomization, with both tests measuring within 15% of one another;
8 Has been receiving no more than two approved disease-specific PAH therapies. PAH therapy must have been at a stable dose for at least 90 days prior to Day 1. No additions or changes should be made to PAH therapies and doses should remain stable for the duration of the study;
etc
Key exclusion criteria
1 Participation in other investigational clinical studies involving interventional products being tested or used in a way different from the approved form or when used for an unapproved indication within 30 days prior to Day 1;
2 Initiation of an exercise program for cardio-pulmonary rehabilitation within 90 days prior to Day1or planned initiation during the study;
3 Stopped receiving any PAH chronic therapy within 60 days prior to Day 1;
4 Stopped receiving any PAH chronic therapy within 60 days prior to Day 1
Received a dose of prednisone 20 mg day (or equivalent dose if other corticosteroid) within 30 days prior to Day 1;
5 Received intravenous or subcutaneous prostacyclin/prostacyclin analogues within 90 days prior to Day 1;
6 Received intravenous inotropes within 30 days prior to Day 1;
7 Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) 160 mm Hg or sitting diastolic BP > 100 mm Hg during Screening after a period of rest
8 Has systolic BP 90 mm Hg during Screening after a period of rest
9 Has a history of clinically significant left-sided heart disease and/or clinically significant cardiac disease, including but not limited to any of the following:
a Congenital or acquired valvular disease if clinically significant apart from tricuspid valvular insufficiency due to pulmonary hypertension;
b Pericardial constriction;
c Restrictive or congestive cardiomyopathy;
d Left ventricular ejection fraction 40% per echocardiogram (ECHO) within 90 days of Day 1;
e Symptomatic coronary artery disease within the last 3 years
10 Acutely decompensated heart failure within 30 days prior to Day 1, per investigator assessment
11 Has more than two of the following clinical risk factors for left ventricular diastolic dysfunction:
a Age 65 years;
b BMI 30 kgm2
c History of systemic hypertension;
d History of type 2 diabetes;
e History of atrial fibrillation
etc
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | Colin |
| Middle name | |
| Last name | Meyer |
Organization
Reata Pharmaceuticals
Division name
Product Development
Zip code
TX 75063
Address
2801 Gateway Drive, Suite 150 Irving
TEL
1-972-865-2202
Colin.Meyer@reatapharma.com
Public contact
Name of contact person
| 1st name | Yukiko |
| Middle name | |
| Last name | Hagihara |
Organization
Labcorp Development Japan K.K.
Division name
Clinical Development Services
Zip code
104-6108
Address
Harumi Toriton Square Office Tower Y 8F 1-8-11, Harumi, Chuo-ku, Tokyo 104-6108
TEL
03-6837-9500
Homepage URL
Yukiko.Hagihara@labcorp.com
Sponsor or person
Institute
Reata Pharmaceuticals, Inc.
Institute
Department
Personal name
Funding Source
Organization
Reata Pharmaceuticals, Inc.
Organization
Division
Category of Funding Organization
Outside Japan
Nationality of Funding Organization
Unites States of America
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
National Hospital Organization Okayama Medical Center Institutional Review Board
Address
1711-1 Tamasu, Kita-ku, Okayama-shi, Okayama
Tel
086-294-9911
chiken-crc@okayamamc.jp
Secondary IDs
Secondary IDs
YES
Study ID_1
US IND NUMBER: 119,235
Org. issuing International ID_1
US IND
Study ID_2
EUDRACT NUMBER: 2016-000196-24
Org. issuing International ID_2
EUDRACT
IND to MHLW
22-1359
Institutions
Institutions
北海道大学病院（北海道）
東北大学病院（宮城県）
群馬大学医学部附属病院（群馬県）
千葉大学医学部附属病院（千葉県）
日本医科大学付属病院（東京都）
北里大学病院（神奈川県）
藤田医科大学病院（愛知県）
独立行政法人国立病院機構 名古屋医療センター（愛知県）
国立研究開発法人 国立循環器病研究センター病院（大阪府）
独立行政法人国立病院機構 岡山医療センター（岡山県）
神戸大学医学部付属病院（兵庫県）
久留米大学医学部附属病院（福岡県）
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 12 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000196-24/results
Number of participants that the trial has enrolled
202
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Main results already published
Date of protocol fixation
| 2016 | Year | 01 | Month | 27 | Day |
Date of IRB
| 2016 | Year | 07 | Month | 29 | Day |
Anticipated trial start date
| 2016 | Year | 09 | Month | 01 | Day |
Last follow-up date
| 2020 | Year | 06 | Month | 12 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2016 | Year | 12 | Month | 06 | Day |
Last modified on
| 2022 | Year | 03 | Month | 11 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028933
